Alector, Inc.
Financials
Valuation Metrics
Alector, Inc.'s Market Cap is $243M. At end of 2025 it was $161M. Ranked #2949 of 3,118 in US market (top 95%), #1342 of 1,474 on NASDAQ (top 91%), #241 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 91%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $243M | US#2,949/3,118 Sec#241/265 |
| Revenue | $14M | US#2,794/3,118 Sec#165/265 |
| Net Income | $-118M | US—/3,118 Sec—/265 |
| Total Assets | $203M | US#2,977/3,118 Sec#242/265 |
| Net Assets | $-10M | US#2,916/3,118 Sec#241/265 |
| Employees | 103 | US#2,606/3,118 Sec#175/265 |
| Value | ||
| P/S | 17.54x | US#2,831/3,118 Sec#139/265 |
| FCF Yield | -65.14% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROA | -58.10% | US#3,009/3,118 Sec#229/265 |
| Op. Margin | -914.56% | US#2,801/3,118 Sec#164/265 |
| Revenue Growth | -82.91% | US#2,715/3,118 Sec#173/265 |
| Financial Health | ||
| Total Debt | $33M | US#2,671/3,118 Sec#170/265 |
| FCF | $-158M | US#2,725/3,118 Sec#185/265 |
| Cash | $60M | US#2,495/3,118 Sec#216/265 |
| Current Ratio | 5.26x | US#445/3,118 Sec#134/265 |
| Performance | ||
| 1Y Return | 44.08% | US#583/3,118 Sec#80/265 |
| 1M Return | 18.38% | US#289/3,118 Sec#22/265 |
| From 52W High | -20.65% | US#1,507/3,118 Sec#88/265 |
| 1Y MDD | -48.71% | US#2,345/3,118 Sec#156/265 |
| Trading | ||
| Volume | 953,908 shares | US#1,541/3,118 Sec#145/265 |
| Trading Value | $2M | US#2,877/3,118 Sec#237/265 |
| Per Share | ||
| EPS | $-1.06 | US—/3,118 Sec—/265 |
| BPS | $-0.09 | US—/3,118 Sec—/265 |
Company Info
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.